Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$250.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

TAISHO PHARMACEUTICAL HOLDINGS Co Ltd to become parent company of Biofermin Pharmaceutical Co Ltd


Wednesday, 26 Feb 2014 01:00am EST 

Biofermin Pharmaceutical Co Ltd:Taisho Pharmaceutical Co., Ltd. to transfer its holding 7,632,021 shares of Biofermin Pharmaceutical Co Ltd to TAISHO PHARMACEUTICAL HOLDINGS Co Ltd, on March 28.TAISHO PHARMACEUTICAL HOLDINGS to become parent company of Biofermin Pharmaceutical with 63.98 pct voting power, while Taisho Pharmaceutical to hold no voting power in Biofermin Pharmaceutical. 

Company Quote

7930.0
20.0 +0.25%
2:00am EDT